Hebei Senlang Biotechnology Inc., Ltd.
Clinical trials sponsored by Hebei Senlang Biotechnology Inc., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Engineered immune cells take on tough T-Cell cancers in new trial Results expected Sep 2026 (estimated)
- Could CAR-T cells tame severe colitis? early trial launches Results expected Feb 2027 (estimated)
- New CAR-T therapy aims to tackle tough childhood leukemia Results expected Mar 2027 (estimated)
- Immune system reset: CAR T-Cells take on autoimmune diseases Results expected Aug 2027 (estimated)
-
Could CAR-T cells tame severe colitis? early trial launches
Disease control Recruiting nowThis early-phase trial tests whether a patient's own immune cells, engineered to target BCMA and/or CD19, can calm severe ulcerative colitis that hasn't responded to other treatments. Twelve adults with moderate-to-severe active disease will receive a single infusion of these CAR…
Early phase 1 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New CAR-T therapy aims to tackle tough childhood leukemia
Disease control Recruiting nowThis phase 2 trial tests a new treatment called Senl_B19 CAR-T cells for people aged 3 to 25 with B-cell acute lymphoblastic leukemia that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to target and kill cancer cel…
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC